What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings?

Q32 Bio Inc. (NASDAQ:QTTB) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Q32 Bio in a report issued on Tuesday, March 10th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.52) for the quarter. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. HC Wainwright also issued estimates for Q32 Bio’s Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.56) EPS and Q4 2026 earnings at ($0.59) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $13.00.

Q32 Bio Stock Performance

Q32 Bio stock opened at $6.91 on Wednesday. The company has a market capitalization of $84.99 million, a price-to-earnings ratio of 3.00 and a beta of 0.14. Q32 Bio has a 1 year low of $1.35 and a 1 year high of $7.10. The company’s 50 day simple moving average is $4.14 and its 200-day simple moving average is $3.09.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings results on Tuesday, March 10th. The company reported $3.65 EPS for the quarter, beating the consensus estimate of ($1.06) by $4.71. The business had revenue of $53.74 million during the quarter.

Insider Buying and Selling at Q32 Bio

In related news, CEO Jodie Pope Morrison sold 9,896 shares of Q32 Bio stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $44,630.96. Following the transaction, the chief executive officer directly owned 89,104 shares in the company, valued at $401,859.04. This trade represents a 10.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders sold 16,706 shares of company stock valued at $75,344. Company insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in QTTB. Marshall Wace LLP purchased a new stake in Q32 Bio in the 2nd quarter valued at approximately $25,000. Acadian Asset Management LLC acquired a new position in shares of Q32 Bio in the 1st quarter valued at $50,000. Two Sigma Investments LP purchased a new stake in Q32 Bio during the third quarter valued at about $62,000. ADAR1 Capital Management LLC purchased a new stake in shares of Q32 Bio during the 4th quarter worth about $66,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Q32 Bio in the first quarter worth $68,000. 31.32% of the stock is owned by hedge funds and other institutional investors.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.